These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7384093)

  • 1. Immunological studies of prostate adenocarcinoma in an animal model.
    Claflin AJ; McKinney EC; Fletcher MA
    Prog Clin Biol Res; 1980; 37():365-77. PubMed ID: 7384093
    [No Abstract]   [Full Text] [Related]  

  • 2. Adenocarcinoma R-3327 of the Copenhagen rat as a suitable model for immunological studies of prostate cancer.
    Lopez DM; Voigt W
    Cancer Res; 1977 Jul; 37(7 Pt 1):2057-61. PubMed ID: 301055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic studies of prostatic cancer using the R3327 rat model.
    Lubaroff DM; Reynolds CW; Culp DA
    Trans Am Assoc Genitourin Surg; 1978; 70():60-5. PubMed ID: 753024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirements for an idealized animal model of prostatic cancer.
    Coffey DS; Isaacs JT
    Prog Clin Biol Res; 1980; 37():379-91. PubMed ID: 7384094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on a weakly immunogenic squamous cell carcinoma of the rat prostate.
    Lande IJ; Feldbush TL; Lubaroff DM
    Invest Urol; 1980 Mar; 17(5):419-24. PubMed ID: 7358506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dunning R3327 prostate adenocarcinoma in the Fischer-Copenhagen F1 rat: a useful model for immunological studies.
    Claflin AJ; McKinney EC; Fletcher MA
    Oncology; 1977; 34(3):105-9. PubMed ID: 917439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rat prostate carcinoma 11095-A: profile of organ- and tumor-specific antigens.
    Lande IJ; Feldbush TL; Lubaroff DM; Bonney WW
    Natl Cancer Inst Monogr; 1978 Dec; (49):283-7. PubMed ID: 86165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel immunological model for the study of prostate cancer.
    Sharma N; Luo J; Kirschmann DA; O'Malley Y; Robbins ME; Akporiaye ET; Lubaroff DM; Heidger PM; Hendrix MJ
    Cancer Res; 1999 May; 59(10):2271-6. PubMed ID: 10344727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of lipoprotein-associated cytotoxic factor on rat prostate adenocarcinoma cells.
    Chan SY; Pollard M
    Cancer Res; 1978 Sep; 38(9):2956-61. PubMed ID: 209892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic characteristics of metastasizing and nonmetastasizing mammary adenocarcinomata of rat.
    Ghosh SK; Roholt OA; Kim U
    Prog Clin Biol Res; 1983; 133():227-33. PubMed ID: 6622494
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunohistologic studies of carcinoma of the prostate. II. Antibodies to prostatic tissue.
    Ablin RJ; Soanes WA; Danaher J
    Z Immunitatsforsch Exp Klin Immunol; 1972; 142(5):432-8. PubMed ID: 4258921
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge.
    Friedman EJ; Orth CR; Brewton KA; Ponniah S; Alexander RB
    J Urol; 1997 Oct; 158(4):1585-8. PubMed ID: 9302178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
    Myers RB; Srivastava S; Grizzle WE
    J Urol; 1995 May; 153(5):1572-4. PubMed ID: 7714977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
    Lane Z; Hansel DE; Epstein JI
    Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Humoral and cellular immunity in prostatic adenocarcinoma].
    Pérez Herrero F; Alfonso Sánchez M; Gutierrez Mínguez E; Urrutia Avisrror M; Montero Gómez J
    Actas Urol Esp; 1983; 7(6):433-6. PubMed ID: 6670612
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative pathology of benign prostatic hyperplasia and prostate cancer.
    Maini A; Archer C; Wang CY; Haas GP
    In Vivo; 1997; 11(4):293-9. PubMed ID: 9292295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.